SANTA MONICA, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), today announced the Company will report on preliminary biomarker data from patients with relapsed/refractory B cell malignancies treated with anti-CD19 chimeric antigen receptor (CAR) T cell therapy in a poster presentation during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), which is taking place in Chicago, May 29 to June 2, 2015. In an ongoing clinical trial at the National Cancer Institute (NCI) being conducted under a Cooperative Research and Development Agreement with Steven A. Rosenberg, M.D., Ph.D., as the NCI Principal Investigator, anti-CD19 CAR T cell therapy has demonstrated durable objective responses in certain lymphomas and leukemias. The poster will be available on May 30th on the Company's website at http://www.kitepharma.com/c/news/publications.php.
ASCO 2015 Poster Presentation
Title: Biomarker Analysis of Patients Treated with Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells.
Abstract: #3028
Poster: #354
Poster Session: Developmental Therapeutics - Immunotherapy
Date and Location: Saturday, May 30, 2015, 8:00am, Central Time; S Hall A, McCormick Place, Chicago, Illinois
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous T cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA.
CONTACT: Kite PharmaCynthia M. Butitta
Chief Financial Officer and Chief Operating Officer
310-824-9999
For Media: Justin Jackson
For Investor Inquiries: Lisa Burns and Carol WertherBurns McClellan
212-213-0006
jjackson@burnsmc.comlburns@burnsmc.comcwerther@burnsmc.com
Kite Pharma, Inc.News Provided by Acquire Media
